

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/870,288	05/29/2001	David K. Swanson	15916-069x	8100
21836	7590 03/03/2006	EXAMINER		
	SLAVIN AND HOLM	PEFFLEY, MICHAEL F		
SUITE 200 840 APOLLO	STREET	ART UNIT	PAPER NUMBER	
EL SEGUNDO	O, CA 90245		3739	

DATE MAILED: 03/03/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

				<u> </u>		
 -			Application No.	Applicant(s)		
			09/870,288	SWANSON ET AL.		
	Office Action Summary		Examiner	Art Unit		
			Michael Peffley	3739		
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
WHIC - Extens after S - If NO - Failure Any re	DRTENED STATUTORY PERIOD HEVER IS LONGER, FROM THE ISSUED OF THE ISSUED	MAILING DA ns of 37 CFR 1.13 nmunication. statutory period w ly will, by statute, a after the mailing	ATE OF THIS COMMUNICATION 6(a). In no event, however, may a reply be tin rill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).		
Status						
1)⊠	Responsive to communication(s) fi	led on <i>17 Ja</i>	nuary 2006.			
<i>,</i> —	•	<u> </u>				
•		n for allowar	lowance except for formal matters, prosecution as to the merits is			
•	closed in accordance with the prac	•				
Disposition	on of Claims	:				
4)	Claim(s) <u>44-114</u> is/are pending in t	he application	on.			
	ta) Of the above claim(s) is/	:				
5)	Claim(s) is/are allowed.	: :				
6)⊠	Claim(s) <u>44-114</u> is/are rejected.	: :				
7)[Claim(s) is/are objected to.	:				
8)□	Claim(s) are subject to restr	iction and/or	r election requirement.			
Application	on Papers	•				
9) The specification is objected to by the Examiner.						
10) 🔲 🗆	The drawing(s) filed on is/ar	e: a) <u>□</u> acce	epted or b) objected to by the	Examiner.		
	Applicant may not request that any ob	ection to the	drawing(s) be held in abeyance. Se	e 37 CFR 1.85(a).		
	Replacement drawing sheet(s) including					
11) 🔲 🛚	The oath or declaration is objected	to by the Ex	aminer. Note the attached Office	Action or form PTO-152.		
Priority u	nder 35 U.S.C. § 119	: :				
12) 🗌 🗸	Acknowledgment is made of a clair	: n for foreign	priority under 35 U.S.C. § 119(a)-(d) or (f).		
_	☐ All b)☐ Some * c)☐ None of:	•				
	1. Certified copies of the priorit	y documents	s have been received.			
	2. Certified copies of the priorit	y documents	s have been received in Applicat	ion No		
	3. Copies of the certified copie	s of the prior	rity documents have been receive	ed in this National Stage		
	application from the Internat	ional Bureau	ı (PCT Rule 17.2(a)).			
* S	ee the attached detailed Office act	ion for a list	of the certified copies not receive	∍d.		
Attachment	t(s)					
_	e of References Cited (PTO-892)		4) Interview Summary			
	e of Draftsperson's Patent Drawing Review		Paper No(s)/Mail D	rate Patent Application (PTO-152)		
	nation Disclosure Statement(s) (PTO-1449 r No(s)/Mail Date "ファ[२](العَّنَا الْعَالَ الْعَالَ الْعَالَ الْعَالَ الْعَالَ الْعَالُ الْعَالَ الْعَالِ الْعَالِي الْعَالِي الْعَالِ الْعَالِ الْعَالِي الْعَالِي الْعَلَى الْعَلَى الْعَلَى الْعَلَى الْعَلَى	or PTO/SB/08)	6) Other:	atom application (1.10-102)		
J.S. Patent and Tr	<u>ં હો પળ્ટે • </u>					
PTOL-326 (R		Office Ad	ction Summary Pa	art of Paper No./Mail Date 02232006		

Art Unit: 3739

Election/Restrictions

Applicant's election without traverse of the invention of Group I and the species of Figure 13 corresponding to claims 44-114 in the reply filed on January 17, 2006 is acknowledged.

It is noted that applicant has indicated that several of the claims have been copied (either exactly or substantially) from three issue patents in order to provoke an interference. All claims in this instant application are rejected under prior art. As such, no interference may be declared at this time. Additionally, the examiner notes that present claims 51 and 52 of the instant application have been denoted as corresponding to claim 1 of US Patent No. 6,117,101. However, claim 1 of the '101 patent clearly sets forth an ultrasonic ablation means, and the instant application contains no disclosure of the use of an ultrasonic ablation means. The examiner deems the claims of the '101 patent to be patentably distinct from the claims of the instant application and sees no reason to justify an interference between the instant application and the '101 patent in view of the instant application's failure to disclose, or claim, the subject matter presented in the claims of the '101 patent.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

⁽e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States

Application/Control Number: 09/870,288

Art Unit: 3739

only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claims 44-53, 57-60, 62, 66-69, 71, 72, 74, 75, 77-80, 84, 86-89, 93-97, 99-102, 106 and 108-111 are rejected under 35 U.S.C. 102(e) as being anticipated by Avitall (5,263,493).

Avitall disclose a tissue ablation device for use the chambers of the heart. The device comprises an elongate member (18) adapted to be positioned adjacent to a circumferential region of tissue, and an ablation element (28) comprising a loop with a plurality of electrodes (36) that is adapted to form a lesion in a circumferential region of tissue. As seen in the figures, the ablation element is a loop (Figures 2 and 6) that is of a size and shape adapted to surround pulmonary veins in the atrium. The loop structure is collapsible (Figure 2B). Figure 4 shows an actuation element to control the shape and deployment of the ablation loop, and no fluid is delivered to tissue during the ablation procedure.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 54-56, 61, 63-65, 70, 81-83, 85, 90-92, 103-105, 107 and 112-114 are rejected under 35 U.S.C. 103(a) as being unpatentable over Avitall ('493) in view of the teaching of Brucker et al (5,500,012).

Application/Control Number: 09/870,288

Art Unit: 3739

The Avitall device has been addressed previously. Avitall disclose the use of individual electrodes to provide for mapping and thermal ablation of tissue. Avitall fail to disclose alternative energy means (i.e. laser, microwave, chemical) for ablation of cardiac tissue. It is noted that applicant's specification makes only a passing suggestion to the use of alternative ablative energy sources, and fails to disclose any of the particulars or show any of the specific arrangements for the various sources of energy. There is no criticality or unexpected result associated with any of the other mentioned energy sources, and applicant's specification shows and describes only RF electrode embodiments.

Brucker et al disclose another cardiac mapping and ablation catheter. The Brucker et al catheter discloses RF energy as the primary ablation energy, but also teaches that it is known to use alternative ablation energy modalities such as laser, microwave, ultrasonic and chemical fluids (col. 2, lines 53-55).

To have provided the Avitall ablation catheter with any well known ablation energy modality to create a lesion in cardiac tissue would have been an obvious consideration for one of ordinary skill in the art, particularly since Brucker et al teach of the known substitutability of the various well-known ablative energy sources in a cardiac ablation device.

Claims 73, 76 and 98 are rejected under 35 U.S.C. 103(a) as being unpatentable over Avitall ('493) in view of the teaching of Webster, Jr (5,411,025).

Application/Control Number: 09/870,288

Art Unit: 3739

Again, the Avitall reference has been addressed. Avitall provide an elongate member (18) with an ablation element (28) attached at the distal end thereof. However, Avitall fail to specifically disclose the use of a catheter through which the ablation element may be deployed into cardiac tissue.

Webster, Jr. discloses another cardiac mapping/ablation catheter that has a deployable ablation element at the distal end of a catheter. In particular, Webster, Jr. teach that it is advantageous to provide an outer sheath (8) through which the ablation member and elongate member may be deployed. The outer sheath allows the device to be inserted into the cardiac tissue prior to deployment of the ablation member.

To have provided the Avitall catheter with a deployment sheath to allow the ablation member to be concealed until it is located in proximity to the treatment tissue would have been an obvious consideration for one of ordinary skill in the art in view of the teaching of Webster, Jr.

Conclusion

The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Kordis et al (5,636,634) and Edwards et al (5,293,869) disclose alternative mapping/ablation catheter systems that could be used to create circumferential lesions in cardiac tissue. Desai (4,940,064) discloses a cardiac ablation catheter with electrode elements that may be deployed to create a circumferential lesion.

Art Unit: 3739

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael Peffley whose telephone number is (571) 272-4770. The examiner can normally be reached on Mon-Fri from 6am-3pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Linda Dvorak can be reached on (571) 272-4764. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

mp February 24, 2006